Basf Se Corporation

Merck Patent Gmbh

University of California

Sandoz Ag

Biomarin Pharmaceutical Inc.

Acadia Pharmaceuticals Inc.

Intervet International B.v.

Anadys Pharmaceuticals, Inc.

Nissan Chemical Industries Limited

Solvias Ag

Ciba Specialty Chemicals Corporation

Teva Pharmaceutical Industries Limited

Ratiopharm Gmbh

Genentech, Inc.

Microbial Chemistry Research Foundation

Fritz Blatter

Martin Szelagiewicz

Rudolf Moser

Viola Groehn

Andreas Hafner

Ruth Boehni Stamm

Thomas Egger

Tobias Hintermann

Tiziana Chiodo

Beate Salvador

Marcus Vossen

Bernd Siebenhaar

Jerry B Evarts

Tjeerd Barf

Edwin Aret

Cecile Krejsa

Emil D Kakkis

Fredric D Price

Bo-Ragnar Tolf

Nathalie Schlienger

Martin Viertelhaus

Paul Van Der Schaaf

Alejandro Dorenbaum

Giuseppe Lapadula

Carl-Magnus A Andersson

David J Kucera

Katharina Reichenbächer

Peter Scott Dragovich

Chinh Viet Tran

Douglas Eric Murphy

Frank Ruebsam

Kai-Uwe Schoening

Paul Adriaan Van Der Schaaf

Erik Philipp

Lawrence Emerson Fisher

Daniel I Oppenheimer

Mikkel Boas Thygesen

Yuefen Zhou

Ulrich Berens

Kai-Uwe Schöning

Gregory Jay Haley

Stefan Reim

Michael Burgert

Karthik Nagapudi

Erik J Rueden

Claudia Marcolli

Manshiu Leung

Monika Brink

Jörg Berghausen

Tim Ingallinera

Heinz M Frei

Hai Sun

Markus Ruettimann

Ralf Warrass

Timo Rager

Lijian Chen

Guixan Hu

Urs Christoph Hofmeier

Walter Weishaar

Markus Von Raumer

Srikonda Sastry

Hans Peter Niedermann

Eva Rödel

Meinrad Brenner

Eva Roedel

Guixian Hu

Tingmin Wang

Brigitte Monika Cron-Eckhardt

Stephan Veit

Tamo Rager

Tingman Wang

Yuan Liu

Collin D Morris

Kerstin Fleischhauer

Katharina Reichenbaecher

Peter Koller

Heinz-Jörg Wennesheimer

Gregory J Haley

Katharina REICHENBÄCHER

Katharina Reichen-BÄCHER

Tanja Schweisel

Ludwig Pilsl

Roland Muller

Markus Frieser

Christine Czauderna

Jorg Berghausen

Heinz-Joerg Wennesheimer

Wei Zhang

Shuai Wang

Rajendra S Tandale

Ramachandran Radhakrishnan

The present invention is directed to a crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid and L-isoleucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to L-isoleucine ethyl ester is from 1:0.3 to 1:2.0 (in mol/mol) and/or hydrates and/or solvates thereof, as well as, a process of obtaining the same.

Crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid and L-isoleucine ethyl ester

The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and an amino acid ethyl ester like L-phenylalanine ethyl ester or L-methionine ethyl ester, wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to amino acid ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.

Crystalline salts of 5-methyl-(6S)-tetrahydrofolic acid and amino ethyl esters

Crystalline monosodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.5 (in mol/mol) and/or hydrates and/or solvates thereof, their use as pharmaceuticals, as well as processes of obtaining the same.

Crystalline monosodium salt of 5-methyl-(6S)-tetrahydrofolic acid

The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.

Crystalline salts of 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester

The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid L-leucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-leucine ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.

Crystalline salts of 5-methyl-(6S)-tetrahydrofolic acid and l-leucine ethyl ester

In some embodiments, the invention relates to crystalline solid forms, including hydrates, polymorphs, and salt forms, of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention relates to amorphous solid forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention also relates to pharmaceutical compositions containing the solid forms, and methods for treating conditions or disorders by administering to a subject a pharmaceutical composition that includes the forms, including pharmaceutical compositions and methods for overcoming the effects of acid reducing agents.

Crystal forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and 4-(2-hydroxyethyl)-morpholine wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to 4-(2-hydroxyethyl)-morpholine is from 1:0.3 to 1:2.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.

Crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and 4-(2-hydroxyethyl)-morpholine

The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:1.51 to 1:2.5 and/or hydrates and/or solvates thereof, as well as, a process of obtaining the same.

Crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid

The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.5 (in mol/mol) and/or hydrates and/or solvates thereof, as well as, a processes of obtaining the same.

The invention relates to novel salts of compounds of the general formula (I), pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia, sickle cell disease and hemochromatosis.

Ferroportin-inhibitor salts

The present invention is directed to crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid comprising

Crystalline binary sodium salts of 5-methyl-(6S)-tetrahydrofolic acid with organic bases

Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate

Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide for treating diffuse large B-cell lymphoma

Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide

Combinations of (3&#x3b2;)-17-(pyridin-3-yl)androsta-5,16-dien-3-yl acetate (Abiraterone acetate) with acidic substances such as citric acid, ascorbic acid, methyl-4-hydroxy benzoate, saccharin, vanillic acid, adipic acid, maleic acid, malic acid, tartaric acid are useful as pharmaceutical preparations and show improved properties such as aqueous solubility and dissolution kinetics, especially in the form of cocrystals or their combination with a suitable acid.

Solid form of abiraterone acetate

Growing community of inventors

Reinach, Switzerland

Fritz Blatter